BDTX vs. ARVN, IOVA, TBPH, XNCR, ATAI, KROS, MNMD, ORGO, TYRA, and MAZE
Should you be buying Black Diamond Therapeutics stock or one of its competitors? The main competitors of Black Diamond Therapeutics include Arvinas (ARVN), Iovance Biotherapeutics (IOVA), Theravance Biopharma (TBPH), Xencor (XNCR), atai Life Sciences (ATAI), Keros Therapeutics (KROS), Mind Medicine (MindMed) (MNMD), Organogenesis (ORGO), Tyra Biosciences (TYRA), and Maze Therapeutics (MAZE). These companies are all part of the "pharmaceutical products" industry.
Black Diamond Therapeutics vs. Its Competitors
Black Diamond Therapeutics (NASDAQ:BDTX) and Arvinas (NASDAQ:ARVN) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, media sentiment, risk, valuation, earnings and dividends.
95.5% of Black Diamond Therapeutics shares are held by institutional investors. Comparatively, 95.2% of Arvinas shares are held by institutional investors. 6.0% of Black Diamond Therapeutics shares are held by insiders. Comparatively, 4.7% of Arvinas shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Black Diamond Therapeutics has a beta of 2.71, meaning that its stock price is 171% more volatile than the S&P 500. Comparatively, Arvinas has a beta of 2.17, meaning that its stock price is 117% more volatile than the S&P 500.
Black Diamond Therapeutics currently has a consensus price target of $12.80, indicating a potential upside of 313.57%. Arvinas has a consensus price target of $20.29, indicating a potential upside of 169.09%. Given Black Diamond Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Black Diamond Therapeutics is more favorable than Arvinas.
Black Diamond Therapeutics has a net margin of 0.00% compared to Arvinas' net margin of -10.92%. Black Diamond Therapeutics' return on equity of 4.70% beat Arvinas' return on equity.
In the previous week, Arvinas had 3 more articles in the media than Black Diamond Therapeutics. MarketBeat recorded 7 mentions for Arvinas and 4 mentions for Black Diamond Therapeutics. Black Diamond Therapeutics' average media sentiment score of 1.45 beat Arvinas' score of 0.55 indicating that Black Diamond Therapeutics is being referred to more favorably in the media.
Black Diamond Therapeutics has higher earnings, but lower revenue than Arvinas. Arvinas is trading at a lower price-to-earnings ratio than Black Diamond Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
Black Diamond Therapeutics beats Arvinas on 12 of the 15 factors compared between the two stocks.
Get Black Diamond Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for BDTX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding BDTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Black Diamond Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:BDTX) was last updated on 7/16/2025 by MarketBeat.com Staff
